Ensysce Biosciences Highlights Notice Of Allowance From US Patent & Trademark Office For ‘Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof’
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Ensysce Biosciences Shares Up 50%; Stock Is A Nano-Cap Name With Recent Interest By Social Media
https://twitter.com/ChrisStarr777/status/1423087368676990980
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's morning session saw 58 companies set new 52-week lows.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)